| Literature DB >> 29140488 |
Libin Jia1, Hongsheng Lin1, Joost Oppenheim1, O M Zack Howard1, Jie Li1, Huiting Fan1, Zhizheng Zhao1, William Farrar1, Ying Zhang1, Nancy Colburn1, Matthew R Young1, Weidong Li1, David Newman1, Barry R O'Keefe1, John Beutler1, Jikai Liu1, Xiaojiang Hao1, Xiaosheng Yang1, Tengfei Ji1, Jeffrey D White1.
Abstract
Since 2007, the US National Cancer Institute (NCI) Office of Cancer Complementary and Alternative Medicine (OCCAM), together with the Cancer Institute of the China Academy of Chinese Medical Sciences (CICACMS), institutes at China Academy of Sciences and Chinese Academy of Medical Sciences, have engaged in collaborations on Chinese medicine (CM) and cancer research. Through these collaborations, CM drugs and compounds have been studied at NCI labs. This paper summarizes the discoveries and progress on these research projects, exploring the aspects of cancer prevention, botanical drug mechanisms of action and component analysis/quality control (QC), and anticancer activity screening. These and other related projects have been presented in various jointly convened workshops and have provided the backdrop for establishing a new organization, the International Consortium for CM and Cancer, to promote international collaborations in this field. Published by Oxford University Press 2017. This work is written by US Government employees and is in the public domain in the US.Entities:
Mesh：
Substances：
Year: 2017 PMID： 29140488 PMCID： PMC6279266 DOI： 10.1093/jncimonographs/lgx007
Source DB: PubMed Journal: J Natl Cancer Inst Monogr ISSN： 1052-6773